Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-04-28 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
董事会关于2024年度带持续经营重大不确定性段落的无保留意见审计报告涉及事项的专项说明
Audit Report / Information Classification · 95% confidence The document is an announcement from the board of directors of Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the audit report for the fiscal year 2024. It specifically discusses the auditor's unqualified opinion with a paragraph on significant uncertainty about the company's ability to continue as a going concern. The document includes detailed explanations about the audit findings, the board's opinions, and the company's planned measures to address the uncertainties. The document references the audit report issued by Ernst & Young Hua Ming LLP and discusses financial figures and risks related to going concern. However, the document itself is not the full audit report but a board announcement explaining the audit report's key points and the company's response. The document length is 2291 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Audit Report / Information (AR), as it focuses on audit findings and related explanations but is not a full annual report or financial statement. FY 2024
2025-04-28 Chinese
董事会关于独立董事2024年度独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a board announcement regarding the independence status of the company's independent directors for the year 2024. It references compliance with regulatory guidelines on independent directors and confirms no conflicts of interest. The content is focused on board/management information rather than financial results, audit, or shareholder voting. The document length is short and it is a formal opinion from the board, not a report or announcement of a report publication. Therefore, it fits best under Board/Management Information (MANG).
2025-04-28 Chinese
2024年度独立董事述职报告（乔友林）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告（乔友林）" which translates to "2024 Annual Independent Director's Work Report (Qiao Youlin)". It is a detailed report by an independent director about his duties, attendance, communication, and oversight activities during the year 2024. The content includes descriptions of meetings attended, communication with auditors and shareholders, and evaluation of company governance and related party transactions. It is not an announcement of a report publication, nor a certification or a brief summary. It is a management-related report focusing on the independent director's role and activities, which fits best under Board/Management Information (MANG). The document length is 3541 characters, which is substantial for a director's report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2025-04-28 Chinese
2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and actual use of raised funds by Beijing Kangle Weishi Biotechnology Co., Ltd. for the year 2024. It includes specifics on fundraising amounts, dates, usage, changes in fund usage, regulatory approvals, and auditor opinions. The content focuses on the management and deployment of capital raised through stock issuances and related regulatory compliance. There is no indication that this is a full annual report, earnings release, or other financial statement. Instead, it is a specialized report on fundraising and capital usage, which aligns with the category of Capital/Financing Update (CAP). The document is lengthy and substantive, not a brief announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CAP with high confidence.
2025-04-28 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on significant events during the quarter. The report covers the period from January to March 2025, indicating it is a quarterly financial report. The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
关于印尼子公司变更注册资本及经营范围的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding changes in the registered capital and business scope of its Indonesian subsidiary. It details the board meeting resolutions approving the capital reduction and business scope adjustment, explains the purpose and impact of these changes, and confirms that these changes do not constitute a major asset restructuring. The document is a corporate announcement about changes in subsidiary capital and operations, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial analysis. It is also not a report publication announcement or a proxy solicitation. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2025-04-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.